The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Long-term follow-up results of the Phase I/II MajesTEC-1 trial
In this video, Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares results from the long-term follow-up of the MajesTEC-1 trial (NCT04557098), which is exploring the safety and efficacy of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
